Pharma's Market
SPECIAL REPORT
MOST SHARED
- With Investors So Bullish, Pullback Must Be Coming
- How to Date a Wall Street Man
- LinkedIn CEO Calms Post-Lockup Concerns
- Why Greece Will Default, Leave the Euro Zone
- Stocks Hold Losses, Italian Banks Downgraded
- Blue Ivy Gets Trademarked By Beyonce And Jay-Z
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- The World's Best Beers
- Housing Still Hurting Consumers, Economy: Bernanke
- Investing in the Fountain of Youth
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- CEO to CEO: Our Roles Are Changing
- Clint Eastwood ‘Surprised’ by Reaction to Chrysler's ‘Halftime in America’ Ad
- Bulls Check In to Community Health
- With Investors So Bullish, Stock Pullback Must Be Ahead
- Is Bill Gross, PIMCO's Bond King, Losing His Touch?
- Greece Austerity Deal Runs Into Trouble Once Again
- Why Greece Will Default, Leave Euro Zone
- Apple’s Record Run: $500 Is a Magic Number
- Private Homebuilders: Dead Men Walking
- Housing Still Hurting Consumers, Economy: Bernanke
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- The World's Best Beers
RSS FEED
Prana Biotechnology: Why I Wanted To Do Their Story
Reporter
![]() |
But there's not much I can do about it. There's a limited amount of airtime on CNBC and whether it's biotech or any other sector, management draws the line on the market cap of companies that we'll highlight. But there are exceptions to the rule. And today there's an example.
Prana Biotechnology [PRAN
Loading...
()
] started out the trading day in the U.S. with a market value of about $75 million. On relatively heavy volume--as I write this--it's crossed the $100 million threshold. Typically not a company I'd be permitted to spend any time covering. But here's why I was able to "sell" what in TV-news lingo we call a "hit" (approximately one minute or the equivalent of maybe two inches of copy in a newspaper) to the producers of "Squawk on the Street" this morning: (You can watch it in the video clip.)
A. It's Alzheimer's Disease, a burgeoning epidemic that affects a lot of viewers.
B. The mostly positive results are from a mid-stage test. That increases the likelihood in today's environment that a pipeline-poor, cash-rich big drug company might come along and partner with or take out the company which doesn't have the money to pay for a large, late-stage clinical trial.
To PR folks who might be reading this, please don't interpret the coverage as setting any kind of precedent and start flooding my inbox or voicemail with a bunch of micro-cap pitches. This was a one-and-done report. In other words, I'm not doing the story on any other CNBC shows today with the exception, of course, of writing about it on this blog. And editorial decisions are made on a case by case basis.
Prana is sanskrit for life force. Namaste.
Questions? Comments?











